<DOC>
	<DOC>NCT00928408</DOC>
	<brief_summary>This is a multicentre, descriptive observational study of adult patients with primary HPT receiving cinacalcet in clinical practice in a number of countries in Europe. Patients will be enrolled within 1 month of initiating cinacalcet treatment, and data will be collected prospectively for up to 1 year from initiation. Data will continue to be collected from patients discontinuing cinacalcet before the end of this period.</brief_summary>
	<brief_title>PRIMARA: A Prospective Descriptive Observational Study to Review Mimpara (Cinacalcet) Use in Patients With Primary Hyperparathyroidism in Clinical Practice</brief_title>
	<detailed_description />
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism, Primary</mesh_term>
	<mesh_term>Cinacalcet Hydrochloride</mesh_term>
	<criteria>at least 18 years of age at the time of first administration of cinacalcet patients with primary HPT who have initiated cinacalcet within 1 month before enrolment in the study provision of informed consent (if required) previous use of cinacalcet (other than within 1 month before enrolment) diagnosed secondary HPT other known aetiology of hypercalcaemia (eg, sarcoidosis, tuberculosis)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>